biomed devic servic
eye look sign execut
new instrument launch popgen
despit solid print continu view factor underpin
hold rate valid name limit visibl control regard
implement scale popgen project abil seamlessli deliv
new instrument launch suitabl premium multipl given
growth outlook acknowledg posit domin market leader
nascent market key enabl breakthrough precis medicin
would look get construct concern prove transitori reiter
hold rate pt
revenu y/i ilmn pre-announc
beat driven y/i growth sequenc consum
lower-than-expect declin microarray consum
beat estim servic revenu
y/i match estim driven up-front payment roch
adj ep y/i came our/street y/i adj gm
y/i beat adj om beat
guid come light expect revenu
flat y/i midpoint prior
y/i ilmn guid assum soft sequenc instrument revenu custom
delay purchas ahead nextseq launch select custom late
on-going weak dtc genom tradit season headwind
sequenc instrument purchas monitor coronaviru outbreak
china plan commun expect impact result gain
clariti model revenu y/i model
revenu approxim full-year total
guide/model reiter revenu growth guid y/i
adj ep prior top line
guid assum revenu linear similar
sequenc consum
growth y/i novaseq consum pull-through
vs averag level sequenc system revenu grow y/i
nextseq launch offset step novaseq placement
sequenc servic flat y/i array y/i high-
teen growth china expect deliv non-gaap gm line
level om expect y/i step non-gaap tax rate
lower rev adj ep
lower rev
adj ep
limit visibl popgen keep us sidelin clear
encourag ilmn recent major announc see page expand
recap tough time reconcil ilmn premium multipl expect
top-lin growth year lower ep guid busi lumpi
vulner larg miss said model top line growth
applaud ilmn recent popul genom win surmis
compani slightli improv visibl pace project
though continu view implement project risk ilmn
uk biobank program run recent expand genom england
gel us-sponsor us project set ramp
price close busi januari
hub precis medicin
domin global leader next gener
sequenc instrument consum
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object
view compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
pt reflect trim estim slightli lower multipl lower price
target use multipl adj ep estim
array servic total services/oth rev y/i line
estim microarray consum y/i beat estim
microarray instrument revenu match microarray servic
rev declin y/i expect full-year array revenu
y/i reflect on-going weak dtc genom
line earli januari announc launch nextseq
expect launch late nextseq expect launch
sequenc system integr edico genom acquir dragen
technolog expect improv time result higher throughput core
lab small medium research lab clinic facil expect
nextseq cannib novaseq custom base high end
nextseq output gigabas low end novaseq output
gigabas clear gap nextseq us list price
nextseq price respect taken earli order
nextseq begin ship limit quantiti also
announc develop new novaseqdx platform expect launch
avail ivd partner like roch content develop
ahead formal launch
ivd partnership roch earli januari enter non-
exclus collabor agreement grant roch right develop distribut
in-vitro diagnost ivd test nextseq system futur diagnost
sequenc system agreement roch develop test
pursu cdx claim trusight oncolog tso exist
pipelin oncolog target therapi term agreement roch
develop manufactur commerci ivd test use nextseq
continu sell nextseq system core sequenc
phase two popgen contract sign genom england earli januari
ink next phase agreement genom england gel deliv
sequenc whole genom end option
increas expect start ramp around middl nh
genom medicin servic provid clinic sampl genom england
uk life scienc strategi provid sampl research purpos
begin fda submiss nipt ivd kit begun fda submiss
trusight nipt ivd kit feedback fda expect fluid
estim nipt assay perform global y/i
move sidelin dont believ premium multipl justifi
compani look grow top line year comp
busi lumpi vulner larg miss said model
top-lin growth what lack visibl growth rate
given wide rang move part would look get construct
concern prove transitori announc genom price point
would meaning acceler top line add headwind
gross oper net incom margin work hard drive cost
sequenc abl usher eagerli await genom think
potenti game-chang sequenc meaning move clinic
research applic
global popul genom project prior pre-announc result
investor concern compani guid revenu ramp
vs popul genom initi turn concern
appropri said encourag uk run uk
biobank initi sequenc genom think may take year
complet latest ndr meet indic good line sight
least global program us million veteran program
genom england phase franc australia singapor four project
manag indic fund issu matter get sign-off
variou constitu stakehold also indic even us
hold unchang target price januari
biomed devic servic
us initi move along slowli compani previous expect
though expect begin ramp said us-bas popul
sequenc project move along slowli expect lack visibl
governments/stakehold ous/emerg countri abl move faster
us deal highli complex requir care planning/design patient
dtc troubl expect dtc genom repres array revenu
reflect on-going weak
lower volum consum genet test meanwhil guidanc
array call declin y/i call illumina ceo franci desouza
indic expect dtc reacceler come year us doesnt
impli recoveri lower convict abil dtc genet
test busi bounc back within next year two perhap longer
china concern china revenu grew
grow concern return growth given trade war concern
possibl competit concern bgi potenti impact coronaviru
cite growth china relat reproduct health nipt oncolog
compani cite reduct research revenu china believ bgi
rel low threat competit unit state concern
possibl could win one larg popul genom project away
hold unchang target price januari
biomed devic servic
detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact inform appear front page report
hold unchang target price januari
biomed devic servic
hold unchang target price januari
biomed devic servic
hold unchang target price januari
biomed devic servic
